Renalytix (STU:2O9) Total Payout Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2O9 Renalytix PLC STU:2O9
12 GF Score
Price €0.07
GF Value €0.04
! 3 Warning Signs
View Full Analysis

What is Renalytix Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Renalytix's current Total Payout Ratio is .

Renalytix Total Payout Ratio Related Terms

Renalytix Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Renalytix's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renalytix Total Payout Ratio Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Payout Ratio
Get a 7-Day Free Trial - - - - -

Renalytix Quarterly Data
Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

STU:2O9 vs VEEV, BTSG, TEM: Total Payout Ratio Comparison

For the Health Information Services subindustry, Renalytix's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renalytix Total Payout Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Renalytix's Total Payout Ratio falls into.


STU:2O9
12GF Score
Renalytix PLC STU:2O9
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renalytix Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Renalytix's Total Payout Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 17.935180668856 + -0) / -18.762958238188
=0.96

Renalytix's Total Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 17.229669796204 + -0) / -3.6392872360591
=4.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Renalytix (STU:2O9) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be overvalued. The current stock price of €0.07 is trading 70% above its estimated GF Value™ of €0.04.

Key valuation signals for STU:2O9:

  • Total Payout Ratio:
  • GF Value™: €0.04 vs. price of €0.07 (70% above fair value)
  • GF Score™: 12/100 with 3 warning signs

No single metric tells the full story. See the STU:2O9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
12GF Score

Get the complete analysis for STU:2O9

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.04
GF Value